This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Rich, S. Articles by Rabinovitch, M. PubMed PubMed Citation Articles by Rich, S. Articles by Rabinovitch, M. Pubmed/NCBI databases Medline Plus Health Information Pulmonary Hypertension Related Collections Other heart failure Pulmonary circulation and disease Other Vascular biology

(Circulation. 2008;118:2190-2199.)
© 2008 American Heart Association, Inc.

Pulmonary Vascular Diseases

Diagnosis and Treatment of Secondary (Non–Category 1) Pulmonary Hypertension

Stuart Rich, MD; Marlene Rabinovitch, MD

From the University of Chicago Pritzker School of Medicine, Chicago, Ill (S.R.); Stanford University School of Medicine, Stanford, Calif (M.R.); and Pulmonary Vascular Research Institute, Chicago, Ill (S.R., M.R.).

Correspondence to Stuart Rich, MD, University of Chicago, Section of Cardiology, 5841 S Maryland Ave, MC 2016, Chicago, IL 60637. E-mail srich@medicine.bsd.uchicago.edu

Key Words: heart failure • hypertension • pulmonary • pulmonary heart disease

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
Pulmonary hypertension occurs commonly in cardiopulmonary disease. In 1998, a new clinical classification was proposed that divided pulmonary hypertension into 5 categories on the basis of the presumed underlying etiology of the pulmonary vascular disease¹ (Table 1). Although it was never intended that this classification be used as a guideline to determine appropriate therapy, somewhat surprisingly, the regulatory authorities decided that all medications that were clinically tested and approved for patients with idiopathic pulmonary arterial hypertension (PAH) and patients with pulmonary hypertension associated with connective tissue diseases be applied to all category 1 patients.² The wisdom of this can be debated at a later date. However, it has left clinicians somewhat confused about the utilization of therapies to treat patients who fall outside of category 1 pulmonary hypertension, often referred to as secondary pulmonary hypertension.

View this table:   Table 1. Current Clinical Classification of Pulmonary Hypertension1

There are 3 classes of approved therapies for PAH, all of which are considered to be pulmonary vasodilators: endothelin receptor blockers, phosphodiesterase-5 inhibitors, and prostacyclins.³ Their clinical efficacy has been based on a short-term improvement in exercise tolerance, as measured by a 6-minute walk test. In all of the clinical trials, an improvement in walk was apparent within the first 4 weeks of use, allowing a judgment about efficacy to be made quickly.⁴ Hemodynamically, their effects are modest, but they tend to raise cardiac output with little effect on pulmonary artery pressure. This has important implications when they are considered for unapproved use. We review . . . [Full Text of this Article]